{"transactions":[{"id":735985,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-16T20:05:08.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control."}],"balance_after":31000,"derivative":{"exercise_price":3.94,"exercise_date":"2027-06-15","expiration_date":"2036-06-14","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001213900-26-069243","document":"marketforms-73180.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000121390026069243/marketforms-73180.xml","form_type":"4"}},{"id":1111280,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:05:06.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control."}],"balance_after":24000,"derivative":{"exercise_price":3.26,"exercise_date":"2026-06-12","expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001213900-25-054280","document":"marketforms-69807.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000121390025054280/marketforms-69807.xml","form_type":"4"}},{"id":1484644,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-10T22:00:10.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control."}],"balance_after":10000,"derivative":{"exercise_price":2.67,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-24-051375","document":"marketforms-66258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000121390024051375/marketforms-66258.xml","form_type":"4"}},{"id":1860840,"issuer":{"id":83618,"kind":"organization","name":"Omega Therapeutics, Inc.","symbol":"OMGA"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T16:05:26.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":18118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":18118,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":18118},"source":{"system":"sec-edgar","filing":"0000899243-23-015150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850838/000089924323015150/doc4.xml","form_type":"4"}},{"id":1861980,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-08T20:10:54.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control."}],"balance_after":10000,"derivative":{"exercise_price":2.85,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-23-047470","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000121390023047470/ownership.xml","form_type":"4"}},{"id":2214217,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-05T21:00:26.000Z","date":"2022-06-30","kind":"purchase","acquired":true,"shares":10000,"price":3.1,"value":31000.0,"ownership":{"direct":true},"balance_after":198000,"source":{"system":"sec-edgar","filing":"0001213900-22-037266","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000121390022037266/ownership.xml","form_type":"4"}},{"id":2236325,"issuer":{"id":83618,"kind":"organization","name":"Omega Therapeutics, Inc.","symbol":"OMGA"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2022-06-10T16:10:30.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":18118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":18118,"derivative":{"exercise_price":3.31,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":18118},"source":{"system":"sec-edgar","filing":"0000899243-22-021895","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850838/000089924322021895/doc4.xml","form_type":"4"}},{"id":2237478,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T20:10:14.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control."}],"balance_after":10000,"derivative":{"exercise_price":3.5,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-22-031989","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000121390022031989/ownership.xml","form_type":"4"}},{"id":2330432,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-16T20:37:48.000Z","date":"2022-03-14","kind":"purchase","acquired":true,"shares":10000,"price":4.25,"value":42500.0,"ownership":{"direct":true},"balance_after":188000,"source":{"system":"sec-edgar","filing":"0001209191-22-019238","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000120919122019238/doc4.xml","form_type":"4"}},{"id":2335133,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-14T20:37:01.000Z","date":"2022-03-10","kind":"purchase","acquired":true,"shares":10000,"price":4.4555,"value":44555.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.28 to $4.50, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":178000,"source":{"system":"sec-edgar","filing":"0001209191-22-018478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000120919122018478/doc4.xml","form_type":"4"}},{"id":2502419,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-11-19T18:30:09.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":547656.26,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"N/A"}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":547656.26},"source":{"system":"sec-edgar","filing":"0001104659-21-141748","document":"tm2133436-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000110465921141748/tm2133436-4_4seq1.xml","form_type":"4"}},{"id":2502418,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T18:30:09.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":6666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of these options is $18.90 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":14.93,"expiration_date":"2024-03-06","underlying":"Common Shares","underlying_shares":6666},"source":{"system":"sec-edgar","filing":"0001104659-21-141748","document":"tm2133436-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000110465921141748/tm2133436-4_4seq1.xml","form_type":"4"}},{"id":2502417,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T18:30:09.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":12.03,"expiration_date":"2030-12-23","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-21-141748","document":"tm2133436-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000110465921141748/tm2133436-4_4seq1.xml","form_type":"4"}},{"id":2621413,"issuer":{"id":83618,"kind":"organization","name":"Omega Therapeutics, Inc.","symbol":"OMGA"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-30T17:05:16.000Z","date":"2021-07-29","kind":"grant","acquired":true,"shares":52941,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable with respect to 25% of the underlying shares on June 2, 2022 and in 36 equal monthly  installments thereafter such that the option will become fully vested and exercisable on June 22, 2025, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":52941,"derivative":{"exercise_price":17,"expiration_date":"2031-07-28","underlying":"Common Stock","underlying_shares":52941},"source":{"system":"sec-edgar","filing":"0000899243-21-030838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850838/000089924321030838/doc4.xml","form_type":"4"}},{"id":2673622,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-11T00:01:39.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control."}],"balance_after":10000,"derivative":{"exercise_price":10.51,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-039680","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000120919121039680/doc4.xml","form_type":"4"}},{"id":2677200,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-08T20:15:57.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in 12 equal monthly installments following June 4, 2021."}],"balance_after":10000,"derivative":{"exercise_price":35.52,"expiration_date":"2031-06-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-004125","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218021004125/primarydocument.xml","form_type":"4"}},{"id":3113122,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T17:31:45.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control."}],"balance_after":9000,"derivative":{"exercise_price":35,"expiration_date":"2030-06-08","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-20-035843","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000120919120035843/doc4.xml","form_type":"4"}},{"id":3113121,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T17:30:19.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":6676,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. (\"Merger Sub\") and ArTara Subsidiary, Inc. (\"ArTara Sub\"). On January 9, 2020 (the \"Effective Time\"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in the Merger in exchange for a stock option to acquire 35,000 shares of ArTara Sub common stock for $1.75 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option shall vest in forty eight (48) approximately equal increments of one hundred thirty nine (139) whole Option Shares beginning on the first day of the first calendar month following December 4, 2018, and then on the first day of each of the next forty seven (47) months thereafter (each a \"Vesting Date\"), if Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being December 1, 2022), all of the Option Shares which had not vested by then (being not less than 139 Option Shares) will vest and become exercisable."}],"balance_after":6676,"derivative":{"exercise_price":9.18,"expiration_date":"2028-12-03","underlying":"Common Stock","underlying_shares":6676},"source":{"system":"sec-edgar","filing":"0001209191-20-035842","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000120919120035842/doc4a.xml","form_type":"4/A","original_submission_date":"2020-01-13"}},{"id":3113120,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T17:30:19.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":12399,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. (\"Merger Sub\") and ArTara Subsidiary, Inc. (\"ArTara Sub\"). On January 9, 2020 (the \"Effective Time\"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in the Merger in exchange for a stock option to acquire 65,000 shares of ArTara Sub common stock for $1.75 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Seven hundred seventy-four (774) of the Option Shares shall vest as of October 1, 2018, and the remaining Option Shares shall vest in forty five (45) approximately equal increments of two hundred fifty eight (258) whole Option Shares beginning on the first day of the fourth calendar month following the date of the grant (being November 1, 2018) and then on the first day of each of the next forty four (44) months thereafter (each a \"Vesting Date\"), if the Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being July 1, 2022), all of the Option Shares which had not vested by then will vest and become exercisable, and that the vesting of all then unvested Option Shares shall be accelerated upon a Change of Control."}],"balance_after":12399,"derivative":{"exercise_price":9.18,"expiration_date":"2028-07-11","underlying":"Common Stock","underlying_shares":12399},"source":{"system":"sec-edgar","filing":"0001209191-20-035842","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000120919120035842/doc4a.xml","form_type":"4/A","original_submission_date":"2020-01-13"}},{"id":3126638,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-02T20:30:46.000Z","date":"2020-05-29","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in 12 equal monthly installments following May 29, 2020."}],"balance_after":10000,"derivative":{"exercise_price":37.66,"expiration_date":"2030-05-29","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-20-004063","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218020004063/primarydocument.xml","form_type":"4"}},{"id":3312470,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-13T23:56:13.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":10491,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. (\"Merger Sub\") and ArTara Subsidiary, Inc. (\"ArTara Sub\"). On January 9, 2020 (the \"Effective Time\"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Received in the Merger in exchange for a stock option to acquire 55,000 shares of ArTara Sub common stock for $1.75 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/48th of the shares subject to the option shall vest monthly following April 29, 2019, for so long as the Reporting Person provides continuous service to the Issuer."}],"balance_after":10491,"derivative":{"exercise_price":9.18,"expiration_date":"2029-04-28","underlying":"Common Stock","underlying_shares":10491},"source":{"system":"sec-edgar","filing":"0001209191-20-003221","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000120919120003221/doc4.xml","form_type":"4"}},{"id":3312469,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-13T23:56:13.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":6676,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. (\"Merger Sub\") and ArTara Subsidiary, Inc. (\"ArTara Sub\"). On January 9, 2020 (the \"Effective Time\"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in the Merger in exchange for a stock option to acquire 35,000 shares of ArTara Sub common stock for $1.75 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option shall vest monthly following January 1, 2019, for so long as the Reporting Person provides continuous service to the Issuer."}],"balance_after":6676,"derivative":{"exercise_price":9.18,"expiration_date":"2028-12-31","underlying":"Common Stock","underlying_shares":6676},"source":{"system":"sec-edgar","filing":"0001209191-20-003221","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000120919120003221/doc4.xml","form_type":"4"}},{"id":3312468,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-13T23:56:13.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":12399,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. (\"Merger Sub\") and ArTara Subsidiary, Inc. (\"ArTara Sub\"). On January 9, 2020 (the \"Effective Time\"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in the Merger in exchange for a stock option to acquire 65,000 shares of ArTara Sub common stock for $1.75 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option shall vest in forty eight (48) approximately equal increments of one thousand one hundred forty five (1,145) whole Option Shares beginning on the first day of the first calendar month following July 12, 2018, and then on the first day of each of the next forty seven (47) months thereafter (each a \"Vesting Date\"), if Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being April 1, 2023), all of the Option Shares which had not vested by then (being not less than 1,184 Option Shares) will vest and become exercisable."}],"balance_after":12399,"derivative":{"exercise_price":9.18,"expiration_date":"2028-07-11","underlying":"Common Stock","underlying_shares":12399},"source":{"system":"sec-edgar","filing":"0001209191-20-003221","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000120919120003221/doc4.xml","form_type":"4"}},{"id":3312467,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-13T23:56:13.000Z","date":"2020-01-10","kind":"grant","acquired":true,"shares":168000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares being reported are being issued pursuant to restricted stock unit awards (\"RSUs\"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 3/24th of the shares were vested upon grant and 1/24th of the shares vest monthly thereafter, beginning on February 10, 2020. Settlement for the RSUs is deferred until the earliest to occur of (i) the Reporting Person's termination of service, (ii) death, (iii) disability and (iv) a change in control of the Issuer. In the event of a change in control of the Issuer, the RSUs will vest in full."}],"balance_after":168000,"source":{"system":"sec-edgar","filing":"0001209191-20-003221","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000120919120003221/doc4.xml","form_type":"4"}},{"id":3501949,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-04T20:17:41.000Z","date":"2019-05-31","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in 12 equal monthly installments following May 31, 2019."}],"balance_after":10000,"derivative":{"exercise_price":43.02,"expiration_date":"2029-05-31","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-19-003291","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218019003291/primarydocument.xml","form_type":"4"}},{"id":3745641,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-03T21:19:09.000Z","date":"2018-11-29","kind":"exercise","acquired":false,"shares":12784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The previously granted option, representing a right to purchase a total of 80,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 24 months thereafter."}],"balance_after":53000,"derivative":{"exercise_price":3.76,"expiration_date":"2025-05-18","underlying":"Common Stock","underlying_shares":12784},"source":{"system":"sec-edgar","filing":"0001562180-18-004775","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004775/primarydocument.xml","form_type":"4"}},{"id":3745640,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-03T21:19:09.000Z","date":"2018-11-29","kind":"sale","acquired":false,"shares":12784,"price":65,"value":830960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-18-004775","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004775/primarydocument.xml","form_type":"4"}},{"id":3745639,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-03T21:19:09.000Z","date":"2018-11-29","kind":"exercise","acquired":true,"shares":12784,"price":3.76,"value":48067.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":12784,"source":{"system":"sec-edgar","filing":"0001562180-18-004775","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004775/primarydocument.xml","form_type":"4"}},{"id":3750156,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-27","kind":"exercise","acquired":false,"shares":716,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The previously granted option, representing a right to purchase a total of 80,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 24 months thereafter."}],"balance_after":65784,"derivative":{"exercise_price":3.76,"expiration_date":"2025-05-18","underlying":"Common Stock","underlying_shares":716},"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3750155,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-27","kind":"exercise","acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following June 1, 2016."}],"balance_after":0,"derivative":{"exercise_price":12.74,"expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3750154,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-27","kind":"exercise","acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following May 24, 2017."}],"balance_after":0,"derivative":{"exercise_price":18.85,"expiration_date":"2027-05-24","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3750153,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-27","kind":"exercise","acquired":false,"shares":4687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The previously granted option, representing a right to purchase a total of 9,375 shares, became exercisable as follows: the option vested in nine equal monthly installments following September 16, 2015."}],"balance_after":0,"derivative":{"exercise_price":22,"expiration_date":"2025-09-16","underlying":"Common Stock","underlying_shares":4687},"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3750152,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-27","kind":"exercise","acquired":false,"shares":883,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vests in 12 equal monthly installments following May 25, 2018."}],"balance_after":7292,"derivative":{"exercise_price":49.45,"expiration_date":"2028-05-25","underlying":"Common Stock","underlying_shares":883},"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3750151,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-26","kind":"exercise","acquired":false,"shares":1721,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vests in 12 equal monthly installments following May 25, 2018."}],"balance_after":8175,"derivative":{"exercise_price":49.45,"expiration_date":"2028-05-25","underlying":"Common Stock","underlying_shares":1721},"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3750150,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":18786,"price":65.03,"value":1221653.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $65.00 to $65.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3750149,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-27","kind":"exercise","acquired":true,"shares":716,"price":3.76,"value":2692.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":18786,"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3750148,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-27","kind":"exercise","acquired":true,"shares":6250,"price":12.74,"value":79625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":18070,"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3750147,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-27","kind":"exercise","acquired":true,"shares":6250,"price":18.85,"value":117812.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":11820,"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3750146,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-27","kind":"exercise","acquired":true,"shares":4687,"price":22,"value":103114.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":5570,"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3750145,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-27","kind":"exercise","acquired":true,"shares":883,"price":49.45,"value":43664.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":883,"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3750144,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-26","kind":"sale","acquired":false,"shares":1721,"price":65,"value":111865.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3750143,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-28T21:20:05.000Z","date":"2018-11-26","kind":"exercise","acquired":true,"shares":1721,"price":49.45,"value":85103.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":1721,"source":{"system":"sec-edgar","filing":"0001562180-18-004727","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004727/primarydocument.xml","form_type":"4"}},{"id":3754422,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-20","kind":"exercise","acquired":false,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The previously granted option, representing a right to purchase a total of 80,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 24 months thereafter."}],"balance_after":66500,"derivative":{"exercise_price":3.76,"expiration_date":"2025-05-18","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754421,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-20","kind":"exercise","acquired":false,"shares":2988,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following June 1, 2016."}],"balance_after":6250,"derivative":{"exercise_price":12.74,"expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":2988},"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754420,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-20","kind":"exercise","acquired":false,"shares":4688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The previously granted option, representing a right to purchase a total of 9,375 shares, became exercisable as follows: the option vested in nine equal monthly installments following September 16, 2015."}],"balance_after":4687,"derivative":{"exercise_price":22,"expiration_date":"2025-09-16","underlying":"Common Stock","underlying_shares":4688},"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754419,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-19","kind":"exercise","acquired":false,"shares":3262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following June 1, 2016."}],"balance_after":9238,"derivative":{"exercise_price":12.74,"expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":3262},"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754418,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-19","kind":"exercise","acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following May 24, 2017."}],"balance_after":6250,"derivative":{"exercise_price":18.85,"expiration_date":"2027-05-24","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754417,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-19","kind":"exercise","acquired":false,"shares":2604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vests in 12 equal monthly installments following May 25, 2018."}],"balance_after":9896,"derivative":{"exercise_price":49.45,"expiration_date":"2028-05-25","underlying":"Common Stock","underlying_shares":2604},"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754416,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-20","kind":"sale","acquired":false,"shares":21176,"price":60.38,"value":1278606.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $60.00 to $60.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754415,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-20","kind":"exercise","acquired":true,"shares":13500,"price":3.76,"value":50760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":21176,"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754414,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-20","kind":"exercise","acquired":true,"shares":2988,"price":12.74,"value":38067.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":7676,"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754413,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-20","kind":"exercise","acquired":true,"shares":4688,"price":22,"value":103136.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":4688,"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754412,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-19","kind":"sale","acquired":false,"shares":600,"price":63.53,"value":38118.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $63.34 to $64.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754411,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-19","kind":"sale","acquired":false,"shares":600,"price":62.81,"value":37686.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $62.06 to $63.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":600,"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754410,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-19","kind":"sale","acquired":false,"shares":10916,"price":60.26,"value":657798.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $60.00 to $60.685. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":1200,"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754409,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-19","kind":"exercise","acquired":true,"shares":3262,"price":12.74,"value":41557.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":12116,"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754408,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-19","kind":"exercise","acquired":true,"shares":6250,"price":18.85,"value":117812.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":8854,"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3754407,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-21T21:26:08.000Z","date":"2018-11-19","kind":"exercise","acquired":true,"shares":2604,"price":49.45,"value":128767.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2604,"source":{"system":"sec-edgar","filing":"0001562180-18-004643","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018004643/primarydocument.xml","form_type":"4"}},{"id":3913899,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-30T20:26:32.000Z","date":"2018-05-25","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in 12 equal monthly installments following May 25, 2018."}],"balance_after":12500,"derivative":{"exercise_price":49.45,"expiration_date":"2028-05-25","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-18-002714","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000156218018002714/primarydocument.xml","form_type":"4"}},{"id":4302735,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":37635,"kind":"person","name":"BESHAR LUKE M","position":1,"cik":"0001192128","reported_name":"BESHAR LUKE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-26T21:00:35.000Z","date":"2017-05-24","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in 12 equal monthly installments following May 24, 2017."}],"balance_after":12500,"derivative":{"exercise_price":18.85,"expiration_date":"2027-05-24","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-17-014569","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1192128/000089924317014569/doc4.xml","form_type":"4"}}]}